Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v14-EN | Version v13-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2020-01-16 | 2020-01-15 |
| Drug Identification Number | 00343617 | 00343617 |
| Brand name | ROFACT | ROFACT |
| Common or Proper name | ROFACT | ROFACT |
| Company Name | BAUSCH HEALTH, CANADA INC. | BAUSCH HEALTH, CANADA INC. |
| Ingredients | RIFAMPIN | RIFAMPIN |
| Strength(s) | 300MG | 300MG |
| Dosage form(s) | CAPSULE | CAPSULE |
| Route of administration | ORAL | ORAL |
| Packaging size | n/a | n/a |
| ATC code | J04AB | J04AB |
| ATC description | DRUGS FOR TREATMENT OF TUBERCULOSIS | DRUGS FOR TREATMENT OF TUBERCULOSIS |
| Reason for shortage | Other (Please describe in comments) | Shortage of an active ingredient. |
| Anticipated start date | 2020-02-15 | 2020-02-15 |
| Actual start date | ||
| Estimated end date | 2020-03-31 | 2020-03-31 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | currently on manual allocation; new API submission, awaiting response from HC | currently on manual allocation |
| Health Canada comments |